Gene · 7423
Papers4,111
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 4,111
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Accelerated wound healing induced by spinach extract in experimental model diabetic rats with streptozotocin. | Sci Rep | 2023 | 37696865 | PubTator, text mining | PubMed |
| Dynamic single-cell regulomes characterize human peripheral blood innate lymphoid cell subpopulations. | iScience | 2023 | 37694139 | PubTator, text mining | PubMed |
| A Review of 10-Year Survivability of Immunotherapy in the Management of Colon Cancer. | Cureus | 2023 | 37692610 | PubTator, text mining | PubMed |
| Association Between Sebum, Total Cholesterol, and Low-Density Lipoprotein (LDL) Cholesterol Levels With Post-acne Keloids. | Cureus | 2023 | 37692568 | PubTator, text mining | PubMed |
| Role of Leptin and Adiponectin in Carcinogenesis. | Cancers (Basel) | 2023 | 37686525 | PubTator, text mining | PubMed |
| Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. | Int J Mol Sci | 2023 | 37686423 | PubTator, text mining | PubMed |
| Enhanced Angiogenesis in HUVECs Preconditioned with Media from Adipocytes Differentiated from Lipedema Adipose Stem Cells In Vitro. | Int J Mol Sci | 2023 | 37686378 | PubTator, text mining | PubMed |
| Unraveling the Angiogenic Puzzle: Pre-Treatment sVEGFR1 and sVEGFR2 Levels as Promising Prognostic Indicators in Early-Stage Breast Cancer Patients. | Int J Mol Sci | 2023 | 37686312 | PubTator, text mining | PubMed |
| Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors. | Int J Mol Sci | 2023 | 37686121 | PubTator, text mining | PubMed |
| Vascular endothelial growth factor B regulates insulin secretion in β cells of type 2 diabetes mellitus mice via PLCγ and the IP3R‑evoked Ca2+/CaMK2 signaling pathway. | Mol Med Rep | 2023 | 37681454 | PubTator, text mining | PubMed |
| Inhibition of LPA-LPAR1 and VEGF-VEGFR2 Signaling in IPF Treatment. | Drug Des Devel Ther | 2023 | 37680863 | PubTator, text mining | PubMed |
| Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. | Nat Cancer | 2023 | 37679568 | PubTator, text mining | PubMed |
| The Ca2+ channel ORAI1 is a regulator of oral cancer growth and nociceptive pain. | Sci Signal | 2023 | 37669398 | PubTator, text mining | PubMed |
| 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept. | Exp Ther Med | 2023 | 37664677 | PubTator, text mining | PubMed |
| Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis. | Medicine (Baltimore) | 2023 | 37657052 | PubTator, text mining | PubMed |
| Treatment of filtration bleb dysfunction after glaucoma surgery by needle revision of filtration bleb combined with conbercept. | Medicine (Baltimore) | 2023 | 37653819 | PubTator, text mining | PubMed |
| Three year outcomes of intravitreal ranibizumab and aflibercept treatment of patients with diabetic macular edema: A comparative study. | Ther Adv Ophthalmol | 2023 | 37649968 | PubTator, text mining | PubMed |
| Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer. | Theranostics | 2023 | 37649596 | PubTator, text mining | PubMed |
| Single-cell RNA reveals a tumorigenic microenvironment in the interface zone of human breast tumors. | Breast Cancer Res | 2023 | 37644609 | PubTator, text mining | PubMed |
| Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD. | Mol Ther Methods Clin Dev | 2023 | 37637380 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7423/papers?page=16